Brought to you by 
AstraZeneca and Palatin work on obesity compounds
07 Sep 2012
Executive Summary
AstraZeneca and Palatin (small-molecule drug discovery) have agreed to work together in the R&D of metabolic compounds that target melanocortin receptors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com